INTRODUCTION
Asthma is characterized by airway hyperreactivity (AHR), eosinophilic airway inflammation, and the Th2 immune response. Natural killer T (NKT) cells are unique CD1d-restricted T cells with surface markers of NK cells, and secrete very large amounts of Th1 or Th2 cytokines immediately following activation. 1 Invariant natural killer T (iNKT) cells have been reported to play an essential role in development of allergen-induced, 2 α-galactosylceramide (α-GalCer)-induced, 3 or ozone-induced 4 AHR in experimental mice. Non-invariant NKT cells may also play a role in development of allergen-induced AHR in a mouse model of asthma. 5 NKT cells may be increased in the airways of patients with asthma, 6 although this is not always the case. 7 We showed an inverse association between blood NKT cells and atopic indexes in stable asthmatics. 8 We found that sputum NKT cells were associated with development of eosinophilic airway inflammation. 9 Recently, we reported that NKT cells may play an important role in the pathogenesis of acute exacerbation in human
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If NKT cells do indeed play an important role in the pathogenesis of asthma in mice and humans, an agent capable of modulating the function of NKT cells may have therapeutic potential to control asthma. α-GalCer-activated iNKT cells have been reported to prevent development of eosinophilic airway inflammation via IFN-γ production. 11 Alternatively, a therapeutic to alter cytokine expression profiles of NKT cells might be considered. In the past several decades, the incidence of asthma and allergic diseases has increased, particularly in developed countries, 12 which may be partly explained by the hygiene hypothesis. 13, 14 The reduction of infectious diseases may pro-has been reported to inhibit development of asthma, suggesting that these Toll-like receptor (TLR) agonists might suppress the functions of iNKT cells. The production of IL-12 from antigen-presenting cells can be induced by exposure of the cells to LPS, 18 flagellin, 19 or CpG. 20 Thus, LPS-, flagellin-, or CpG-induced changes in the microenvironmental cytokine milieu may modify the function of iNKT cells in asthma via IFN-γ production. Additionally, anergy or hyporesponsiveness of iNKT cells can result following activation by α-GalCer [21] [22] [23] or bacteria. 19 IL-12 might play a role in induction of iNKT cell anergy following microorganism-induced iNKT cell activation, 19 which might be a therapeutic modality to induce iNKT cell tolerance in asthma.
In the present study, we investigated whether LPS, flagellin, or CpG can inhibit the function of airway iNKT cells using a mouse model of α-GalCer-induced AHR. Intranasal administration of α-GalCer has been used to demonstrate the presence of iNKT cells in the lungs and airways, showing increased AHR 24 hours post-administration. 3 Additionally, using mouse spleen iNKT cells, we determined the suppressive effects of LPS, flagellin, and CpG on spleen iNKT cells. The results are consistent with the proposal that TLR4, 5, and 9 agonists suppress the function of airway and spleen iNKT cells via IL-12-dependent mechanisms.
MATERIALS AND METHODS

Mice
Female, six-week-old, BALB/c mice were purchased from Orient Bio (Seongnam, South Korea). Mice were bred in a laminar flow holding unit and housed in autoclaved cages on autoclaved bedding. Chonnam National University Medical School Committee on Animal Welfare approved the animal protocols.
Measurement of α-GalCer-induced AHR
Naïve mice were intranasally administered 1 μg α-GalCer (Enzo Life Sciences, Lausen, Switzerland) or PBS. AHR to methacho- Fig. 1 . Effect of lipopolysaccharide (LPS) on α-galactosylceramide (GalCer)-induced airway hyperreactivity (AHR), airway inflammation, and cytokine production. Naïve mice were intranasally administered α-GalCer or phosphate-buffered saline (PBS). Twenty-four hours later, AHR to methacholine (A), inflammatory cells (B), and cytokines (C, D, and E) in bronchoalveolar lavage (BAL) fluid were measured. LPS was intranasally administered 24 hr before α-GalCer administration. LPS alone denotes administration of LPS without α-GalCer. Enhanced pause (Penh) was expressed as the percentage increase in Penh, where Penh after PBS represented 100%. AAIR line was measured using a model OCP-3000 barometric plethysmographic chamber (Allmedicus, Anyang, South Korea) 24 hours after α-GalCer administration, as described previously.
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Analysis of bronchoalveolar lavage (BAL) fluid
Immediately after the AHR measurements, BAL was evaluated as described previously. 24 Total cells, macrophages, lymphocytes, eosinophils, and neutrophils were counted. Supernatants were kept for cytokine assays.
Cultures of α-GalCer-stimulated spleen cells
Spleens were removed from naïve mice. Spleen cells were incubated in RPMI 1640 media (WelGENE, Daegu, South Korea) for 16 hours, and then stimulated with 0.1 μg/mL α-GalCer. After 90 minutes, intracellular cytokines of iNKT cells were stained.
Flow cytometry for staining of intracellular cytokines of iNKT cells
Spleen iNKT cells were identified by staining with peridininchlorophyll protein-conjugated CD3 mAb (BD Biosciences, San Jose, CA, USA) and phycoerythrin-conjugated CD1d tetramers (Pro Immune, Sarasota, FL, USA) loaded with α-GalCer. Unloaded CD1d tetramers were used as a control. For intracellular staining, fixation and permeabilization were performed using Cytofix/Cytoperm kits (BD Biosciences), according to the manufacturer's instructions. Cells were incubated with allophycocyanin-conjugated IL-4 (BD Biosciences) or IFN-γ mAbs (BD Biosciences), and the respective isotype IgG1 antibodies (BD Biosciences). Flow cytometry was performed using a four-color BD FACS Calibur instrument (BD Biosciences) and analyzed with FlowJo 8.7.1 software (Tree Star, Ashland, OR, USA).
Treatment with LPS, flagellin, or CpG
In a model of α-GalCer-induced AHR, 0.1 µg LPS (Sigma-Aldrich), 10 µg flagellin, or 50 µg of CpG oligodeoxynucleotide (InvivoGen, San Diego, CA, USA) was intranasally administered 24 hours before α-GalCer administration. In our preliminary study, intranasal treatment with 0.1 μg LPS seemed to inhibit development of α-GalCer-induced AHR and airway inflammation more effectively than 3 or 100 μg LPS. In spleen cultures, LPS (0.5 ng/mL), flagellin (0.1 μg/mL), or CpG (0.1 μg/mL) was added 16 hours before α-GalCer stimulation. Vibrio vulnificus- derived recombinant flagellin B (FlaB) was used, which was cloned and purified as described previously.
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Treatment with anti-IL-12 mAb IL-12p70 mAb (100 μg; BD Biosciences) or isotype IgG2b (BD Biosciences) was administered intraperitoneally immediately before treatment with LPS, FlaB, or CpG in a model of α-GalCerinduced AHR. In spleen cultures, IL-12p70 mAb (10 μg/mL) was added immediately before treatment with LPS, FlaB, or CpG.
Enzyme-linked immunosorbent assay (ELISA) for cytokine measurements
IL-4, IL-12, IL-13, and IFN-γ levels in BAL fluid were measured by ELISA (R&D Systems, Minneapolis, MN, USA), as described previously. 24 
Statistical analysis
Mann-Whitney U-tests were used to compare the two groups (SPSS version 17.0 for Windows; SPSS, Chicago, IL, USA). A P value less than 0.05 was deemed to be statistically significant.
RESULTS
Effect of LPS, FlaB, or CpG treatment on α-GalCer-induced AHR, airway inflammation, and cytokine responses
Intranasal treatment with LPS 24 hours before α-GalCer administration inhibited development of α-GalCer-induced AHR. Treatment with LPS alone did not induce AHR. Administration of α-GalCer increased numbers of total cells, as well as of macrophages, eosinophils, neutrophils, and lymphocytes, all of which were decreased by LPS treatment. Treatment with LPS alone slightly increased inflammatory cell numbers. α-GalCer administration enhanced production of both IL-13 and IFN-γ, which were inhibited by LPS treatment. Treatment with LPS alone resulted in no production of IL-13 or IFN-γ. Administration of LPS, but not α-GalCer, induced IL-12 production (Fig. 1) . Thus, these findings indicate that intranasal LPS treatment may enhance IL-12 production, and then suppress the function of iNKT cells in the airways.
Intranasal treatment with FlaB 24 hours before α-GalCer administration decreased α-GalCer-induced AHR and inflamma- (Fig. 2) . These data indicate that intranasal FlaB treatment enhances IL-12 production, and then suppresses the function of iNKT cells in the airways.
Intranasal treatment with CpG 24 hours before α-GalCer administration decreased α-GalCer-induced AHR and inflammatory cell numbers. Treatment with CpG decreased both IL-4 and IFN-γ, but enhanced IL-12, production (Fig. 3) . The results indicate that intranasal CpG treatment may enhance IL-12 production and then suppress the function of iNKT cells in the airways.
Role of IL-12 for the suppressive effect of LPS, FlaB, or CpG
Injection of IL12 mAb, but not the IgG2b isotype, reversed the suppressive effects of LPS, FlaB, and CpG on development of α-GalCer-induced AHR. The reduced numbers of α-GalCerinduced inflammatory cells caused by intranasal LPS, FlaB, or CpG treatment returned to those of α-GalCer-induced inflammatory cells in mice treated with IL-12 mAb, but not the IgG2b isotype. The reduced levels of IL-4, IL-13, and IFN-γ caused by intranasal LPS, FlaB, or CpG treatment returned to those of α-GalCer-induced cytokines in mice treated with IL-12 mAb, but not the IgG2b isotype (Figs. 4-6 ). These data indicate that intranasal LPS, FlaB, or CpG treatment may suppress the function of iNKT cells in the airways in an IL-12-dependent manner.
Effect of LPS, FlaB, or CpG on spleen iNKT cells
We examined whether the IL-12-dependent suppressive effect of intranasal treatment with LPS, FlaB, or CpG on airway iNKT cells was also reproduced in spleen iNKT cells. Intracellular cytokines of iNKT cells were stained in α-GalCer-stimulated spleen cell cultures pretreated with LPS, FlaB, or CpG in the presence and absence of IL-12 mAb (Fig. 7A) . Numbers of IL-4+ or IFN-γ + iNKT cells were increased in α-GalCer-stimulated cells compared with non-stimulated cells, but decreased in α-GalCer-stimulated cells that had been pretreated 24 hours earlier with LPS, compared with α-GalCer-stimulated cells. However, the addition of anti-IL-12 mAb, but not isotype, to LPS-pretreated and α-GalCer-stimulated spleen cells reversed the reduced number of IL-4+ or IFN-γ + cells to the level in α-GalCer-stimulated spleen cells ( Fig. 7B and C) . These findings indicate that LPS treatment suppresses the function of (Fig. 7D and E) . These data suggest that FlaB treatment suppresses the function of spleen iNKT cells in an IL-12-dependent manner.
Pretreatment with CpG decreased the number of IL-4+ or IFN-γ + iNKT cells in α-GalCer-stimulated spleen cells. The reduced number of IL-4+ or IFN-γ + cells was restored to the level in α-GalCer-stimulated spleen cells by addition of anti-IL-12 mAb, but not isotype (Fig. 7F and G) . These findings indicate that CpG treatment may suppress the function of spleen iNKT cells in an IL-12-dependent manner.
DISCUSSION
In the present study, treatment with a TLR4, 5, or 9 agonist inhibited the function of iNKT cells in both airways and spleen, which was abrogated by treatment with IL-12 mAb, suggesting that the TLR agonists inhibited the function of iNKT cells in an IL-12-dependent fashion in asthma. Thus, these three TLR agonists may be used as an immunomodulator for iNKT cells in asthma.
All three TLR agonists increased production of IL-12 in BAL fluid, which was consistent with the findings of other studies. 18, 25, 26 We wondered how IL-12 could inhibit production of both IL-4 and IFN-γ from α-GalCer-stimulated iNKT cells. The finding that IL12 mAb treatment eliminated the suppressive effect of IL-12 on production of IL-4 and IFN-γ may suggest a requirement for IL-12 in the suppressed production of Th1 and Th2 cytokines. This phenomenon may be explained by iNKT cell anergy or hyporesponsiveness induced by IL-12. Anergy is one of the mechanisms of peripheral T cell tolerance. Exposure of CD4+ T cells to an antigen may make the cells incapable of subsequently responding to that antigen. 27 Some studies have suggested that stimulation of iNKT cells with α-GalCer may result in an anergic state to subsequent stimulation following the initial activation. [21] [22] [23] iNKT cell anergy has been associated with http://e-aair.org down-regulation of invariant T cell receptor. 21 The kinetics of initial iNKT cell activation, expansion, and induction of anergy in response to α-GalCer stimulation has been suggested to resemble the responses of T cells to superantigen. 22 iNKT cells might be activated by microorganisms non-specifically via production of proinflammatory cytokines by dendritic cells (DCs), such as type I IFN 28 or IL-12. 18, 19, 29 A recent study has demonstrated that mouse iNKT cells activated by LPS or flagellin become anergic to subsequent activation with α-GalCer, and that IL-12 may play a critical role in induction of iNKT cell anergy. 19 Thus, the IL-12 produced by DCs stimulated with TLR agonists may activate iNKT cells non-specifically, resulting in induction of iNKT cell anergy. It has been reported that IL-12-induced iNKT cell anergy may be associated with the downregulation of NK1.1, the activating NK cell receptor NKG2D and the CD94 subunit of the NKG2/CD94 family of NK cell receptors, may be induced independently of thymus, may be predominantly iNKT cell autonomous, and can been overcome by treatment with reagents that can bypass early T cell receptor signaling events. 19 However, further studies are needed to elucidate the precise mechanisms of iNKT cell anergy.
However, IL-12 may lead to production of IFN-γ from iNKT cells. LPS-stimulated DCs produce IL-12, which induced IFN-γ, but not IL-4, production by iNKT cells. 18, 29 CpG-stimulated DCs also activate NKT cells via IL-12 secretion, in which NKT cells produce IFN-γ, but not IL-4. 20 In contrast, in the present study, IL-12 inhibited production of both IL-4 and IFN-γ. It seems reasonable to suggest that IL-12-activated iNKT cells may produce IFN-γ at an earlier stage, but that iNKT cell anergy develops at a later stage. However, treatment with LPS, flagellin, or CpG alone did not increase IFN-γ levels in BAL fluid obtained after two days. IFN-γ production would be found to have increased had the levels been measured at an earlier time point. IFN-γ cytokine production by iNKT cells has been reported to peak 12 hours after α-GalCer stimulation. 30 Various infectious stimuli, such as TLR ligands, may be expected to suppress asthma and allergic diseases. Indeed, LPS has been reported to attenuate allergic airway diseases. 15 We previously reported that intranasal administration of flagellin may inhibit development of allergic asthma. 16 CpG may suppress 
AAIR
http://e-aair.org development of allergic asthma. 17 Our results may in part explain why treatment with LPS, flagellin, and CpG suppresses development of allergic asthma., Indeed, a TLR7 agonist was recently reported to inhibit development of allergic asthma. 31 Taken together, our data support the view that TLR4, 5, and 9 agonists may suppress the function of airway and spleen iNKT cells via IL-12-dependent mechanisms. iNKT cell anergy induced by IL-12 may play a role in the suppression by TLR agonists. Thus, LPS, flagellin, and CpG, as new immunomodulators of iNKT cells, may be used to control asthma. Further studies will be needed to elucidate how precisely IL-12 induces iNKT cell anergy.
